La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Eurofins Scientific Croissance future
Future contrôle des critères 3/6
Eurofins Scientific devrait augmenter ses bénéfices et son chiffre d'affaires de 18.3% et de 7.6% par an respectivement. Le BPA devrait croître de de 17.9% par an. Le rendement des capitaux propres devrait être 11.5% dans 3 ans.
Informations clés
18.3%
Taux de croissance des bénéfices
17.9%
Taux de croissance du BPA
| Life Sciences croissance des bénéfices | 25.4% |
| Taux de croissance des recettes | 7.6% |
| Rendement futur des capitaux propres | 11.5% |
| Couverture par les analystes | Good |
| Dernière mise à jour | 20 Aug 2024 |
Mises à jour récentes de la croissance future
Results: Eurofins Scientific SE Beat Earnings Expectations And Analysts Now Have New Forecasts
Jul 27
Recent updates
Earnings Tell The Story For Eurofins Scientific SE (EPA:ERF)
Aug 17Results: Eurofins Scientific SE Beat Earnings Expectations And Analysts Now Have New Forecasts
Jul 27These 4 Measures Indicate That Eurofins Scientific (EPA:ERF) Is Using Debt Extensively
May 10We Discuss Why Eurofins Scientific SE's (EPA:ERF) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year
Apr 19Eurofins Scientific SE's (EPA:ERF) Price In Tune With Earnings
Apr 18Does Eurofins Scientific (EPA:ERF) Have A Healthy Balance Sheet?
Nov 10Eurofins Scientific SE's (EPA:ERF) Intrinsic Value Is Potentially 64% Above Its Share Price
Oct 23We Think Eurofins Scientific (EPA:ERF) Is Taking Some Risk With Its Debt
Aug 07Are Investors Undervaluing Eurofins Scientific SE (EPA:ERF) By 25%?
Jul 20We Think Eurofins Scientific (EPA:ERF) Can Stay On Top Of Its Debt
May 03Eurofins Scientific SE (EPA:ERF) Shares Could Be 21% Above Their Intrinsic Value Estimate
Apr 11Estimating The Intrinsic Value Of Eurofins Scientific SE (EPA:ERF)
Jan 05Here's Why Eurofins Scientific (EPA:ERF) Can Manage Its Debt Responsibly
Dec 14An Intrinsic Calculation For Eurofins Scientific SE (EPA:ERF) Suggests It's 33% Undervalued
Oct 03Does Eurofins Scientific (EPA:ERF) Have A Healthy Balance Sheet?
Sep 06Eurofins Scientific (EPA:ERF) Is Increasing Its Dividend To €1.00
Jun 25Are Investors Undervaluing Eurofins Scientific SE (EPA:ERF) By 39%?
Jun 16Eurofins Scientific (EPA:ERF) Has A Rock Solid Balance Sheet
Jun 01Should You Be Adding Eurofins Scientific (EPA:ERF) To Your Watchlist Today?
Apr 12These 4 Measures Indicate That Eurofins Scientific (EPA:ERF) Is Using Debt Safely
Feb 25Is Eurofins Scientific SE (EPA:ERF) Worth €114 Based On Its Intrinsic Value?
Nov 28Eurofins Scientific (EPA:ERF) Has A Rock Solid Balance Sheet
Nov 14Here's Why I Think Eurofins Scientific (EPA:ERF) Might Deserve Your Attention Today
Sep 30Are Eurofins Scientific SE (EPA:ERF) Investors Paying Above The Intrinsic Value?
Aug 29We Think Eurofins Scientific (EPA:ERF) Can Manage Its Debt With Ease
Aug 15Do Eurofins Scientific's (EPA:ERF) Earnings Warrant Your Attention?
Jun 24Estimating The Fair Value Of Eurofins Scientific SE (EPA:ERF)
May 25Eurofins Scientific (EPA:ERF) Has A Rock Solid Balance Sheet
Mar 31Does Eurofins Scientific (EPA:ERF) Deserve A Spot On Your Watchlist?
Mar 17Eurofins Scientific SE (EPA:ERF) Has Got What It Takes To Be An Attractive Dividend Stock
Mar 03Eurofins Scientific SE Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Mar 03Are Institutions Heavily Invested In Eurofins Scientific SE's (EPA:ERF) Shares?
Feb 15
Is Eurofins Scientific's (EPA:ERF) 117% Share Price Increase Well Justified?
Dec 28How Does Eurofins Scientific's (EPA:ERF) CEO Pay Compare With Company Performance?
Dec 14Eurofins Scientific (EPA:ERF) Is Growing Earnings But Are They A Good Guide?
Nov 30Prévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 12/31/2026 | 8,137 | 630 | 811 | 1,520 | 13 |
| 12/31/2025 | 7,570 | 529 | 702 | 1,373 | 14 |
| 12/31/2024 | 7,030 | 428 | 599 | 1,219 | 16 |
| 6/30/2024 | 6,724 | 326 | 674 | 1,215 | N/A |
| 3/31/2024 | 6,619 | 291 | 571 | 1,117 | N/A |
| 12/31/2023 | 6,515 | 257 | 468 | 1,018 | N/A |
| 9/30/2023 | 6,512 | 335 | 403 | 995 | N/A |
| 6/30/2023 | 6,510 | 414 | 339 | 971 | N/A |
| 3/31/2023 | 6,611 | 497 | 407 | 1,054 | N/A |
| 12/31/2022 | 6,712 | 581 | 476 | 1,136 | N/A |
| 9/30/2022 | 6,785 | 612 | 602 | 1,219 | N/A |
| 6/30/2022 | 6,857 | 643 | 727 | 1,301 | N/A |
| 3/31/2022 | 6,787 | 696 | 866 | 1,406 | N/A |
| 12/31/2021 | 6,718 | 749 | 1,005 | 1,511 | N/A |
| 9/30/2021 | 6,553 | 786 | 1,023 | 1,499 | N/A |
| 6/30/2021 | 6,388 | 824 | 1,041 | 1,487 | N/A |
| 3/31/2021 | 5,913 | 665 | 955 | 1,355 | N/A |
| 12/31/2020 | 5,439 | 505 | 868 | 1,224 | N/A |
| 9/30/2020 | 5,079 | 347 | 713 | 1,057 | N/A |
| 6/30/2020 | 4,719 | 190 | 558 | 891 | N/A |
| 3/31/2020 | 4,641 | 168 | 457 | 784 | N/A |
| 12/31/2019 | 4,563 | 146 | 355 | 678 | N/A |
| 9/30/2019 | 4,384 | 144 | 300 | 618 | N/A |
| 6/30/2019 | 4,205 | 143 | 244 | 558 | N/A |
| 3/31/2019 | 3,993 | 159 | 212 | 551 | N/A |
| 12/31/2018 | 3,781 | 175 | 180 | 544 | N/A |
| 9/30/2018 | 3,549 | 182 | 179 | 521 | N/A |
| 6/30/2018 | 3,318 | 190 | 178 | 498 | N/A |
| 3/31/2018 | 3,145 | 185 | N/A | 451 | N/A |
| 12/31/2017 | 2,971 | 179 | N/A | 405 | N/A |
| 9/30/2017 | 2,848 | 166 | N/A | 387 | N/A |
| 6/30/2017 | 2,725 | 152 | N/A | 369 | N/A |
| 3/31/2017 | 2,631 | 145 | N/A | 370 | N/A |
| 12/31/2016 | 2,537 | 138 | N/A | 372 | N/A |
| 9/30/2016 | 2,427 | 104 | N/A | 350 | N/A |
| 6/30/2016 | 2,317 | 69 | N/A | 328 | N/A |
| 3/31/2016 | 2,133 | 63 | N/A | 310 | N/A |
| 12/31/2015 | 1,950 | 56 | N/A | 291 | N/A |
| 9/30/2015 | 1,779 | 71 | N/A | 274 | N/A |
| 6/30/2015 | 1,609 | 86 | N/A | 256 | N/A |
| 3/31/2015 | 1,509 | 82 | N/A | 234 | N/A |
| 12/31/2014 | 1,410 | 78 | N/A | 212 | N/A |
| 9/30/2014 | 1,355 | 66 | N/A | 187 | N/A |
| 6/30/2014 | 1,299 | 53 | N/A | 162 | N/A |
| 3/31/2014 | 1,262 | 53 | N/A | 166 | N/A |
| 12/31/2013 | 1,226 | 53 | N/A | 169 | N/A |
| 9/30/2013 | 1,180 | 61 | N/A | 159 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de ERF ( 18.3% par an) est supérieure au taux d'épargne ( 1.2% ).
Bénéfices vs marché: Les bénéfices de ERF ( 18.3% par an) devraient croître plus rapidement que le marché French ( 12.3% par an).
Croissance élevée des bénéfices: Les bénéfices de ERF devraient augmenter, mais pas de manière significative.
Chiffre d'affaires vs marché: Le chiffre d'affaires de ERF ( 7.6% par an) devrait croître plus rapidement que le marché French ( 5.8% par an).
Croissance élevée des revenus: Le chiffre d'affaires de ERF ( 7.6% par an) devrait croître plus lentement que 20% par an.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Le retour sur capitaux propres de ERF devrait être faible dans 3 ans ( 11.5 %).